Research Repository

Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats

Wallingford, Nicholas G, Sinnayah, Puspha, Bymaster, Frank P, Gadde, Kishore M, Krishnan, Ranga K, McKinney, Anthony A, Landbloom, Ronald P, Tollefson, Gary D and Cowley, Michael A (2008) Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology, 33 (12). pp. 2922-2933. ISSN 0893-133X (print) 1740-634X (online)

Full text for this resource is not available from the Research Repository.

Abstract

Olanzapine (OLZ), one of the second-generation atypical antipsychotics (SGAs), has shown relative advantages in patient adherence and outcomes. However, OLZ has also been associated with a higher incidence of weight gain than most other SGAs. Excessive weight gain may in turn contribute to long-term health concerns for some individuals. Zonisamide (ZNS), a medication approved in the United States as an adjunct in the management of epilepsy, has a diverse pharmacological profile, including sodium channel blockade, monoamine enhancement, and inhibition of carbonic anhydrase. ZNS has also been reported to cause weight loss in both humans and rodents. We hypothesized that this profile might be beneficial when co-administered with OLZ. To test this hypothesis, we evaluated the effects of OLZ on body weight, as well as the pathways known to regulate feeding behavior and arousal in the Sprague–Dawley rat. As indicated via c-Fos expression, we found an OLZ-induced activation in the nucleus accumbens and orexin neurons in the lateral hypothalamus. An OLZ-associated development of hyperphagia, weight gain and elevated blood glucose in the rat was also found. These outcomes were attenuated and reversed in the presence of concomitant ZNS. These results suggest the hypothesis that ZNS may effectively treat or prevent weight gain or metabolic changes associated with the SGAs. Future studies of this combination in patients through appropriately designed human clinical studies are encouraged.

Item Type: Article
Uncontrolled Keywords: ResPubID22029. antipsychotic drugs, c-Fos, diabetes, obesity, orexin, therapy, immunohistochemistry, psychotropic
Subjects: Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
FOR Classification > 1101 Medical Biochemistry and Metabolomics
FOR Classification > 1103 Clinical Sciences
Depositing User: VUIR
Date Deposited: 24 May 2012 02:58
Last Modified: 03 Feb 2015 05:28
URI: http://vuir.vu.edu.au/id/eprint/7992
DOI: https://doi.org/10.1038/npp.2008.9
ePrint Statistics: View download statistics for this item
Citations in Scopus: 31 - View on Scopus

Repository staff only

View Item View Item

Search Google Scholar